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Neuroangiogenesis: 
a vascular basis for Alzheimer’s disease (AD) 
and cognitive decline during aging 
Abstract 
Angiogenesis directs development of the brain’s microcirculation during antenatal 
and postnatal development, but its role later in life is less well recognized.  I content that 
during senescence a reduced cerebral capillary density (CCD) accounts in part for the 
vascular cognitive impairment (VCI) observed in many older persons and possibly for some 
forms of Alzheimer’s disease (AD).  I propose that neuroangiogenesis (NAG) is essential 
throughout adult life for maintaining the microcirculation of the cerebral cortex and 
elsewhere in the brain and that it commonly declines with old age.  To support this 
hypothesis I have examined the neurological literature for relevant studies on CCD and NAG 
throughout the three stages of life and in persons with senile dementias.  Finally, I discuss 
therapeutic approaches employing angiogenic factors for treating VCI and AD. 
 
Key words:  capillary density, angiogenesis, senile dementias, Alzheimer’s disease, vascular   
                  cognitive impairment 
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Neuroangiogenesis: 
a vascular basis for Alzheimer’s disease (AD) 
and cognitive decline during aging 
(8039 words … 10 June 12, 2012) 
 
1.  Introduction 
 Throughout the world senile dementias affect 5-7% of people over age 60.  This 
number is expected to double in the next 20 years [1].   In the United States at present, 
Alzheimer’s disease (AD) afflicts13% of persons age 65 or older and 43% of  
those 85 and older, or an estimated 5.4 million [2].  By 2030 the number of persons in the 
country with AD is expected to reach 7.7 million and by 2050 will approach 11 to 16 million -- 
“barring the development of medical breakthroughs to prevent or more effectively treat the 
disease” [2].  
 The pathogenesis of senile dementias is likely to be mutifactorial and involve 
several or many sequential cellular and biological interactions.  However, most investigators 
have focused their attention mainly on one particular etiopathology.  For example, I suggest 
that there is a common denominator accounting for the cognitive decline experienced by 
many aged people and the localized motor skills highly developed in young intensely trained 
musicians – namely, the microcirculation and the attendant level of angiogenesis in the 
brain.  In a 2010 paper in the American Scientist I proposed that the remarkable 
finger/hand/foot dexterity displayed by concert pianists is due not only to augmented 
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synaptic connections in the primary motor cortex but also to an increased local capillary 
density -- initiated and maintained there by continuing angiogenesis [3]. 
 The involvement of angiogenesis in cerebral capillary development during the early 
postnatal period has been established, but its function during maturity and old age is less 
well understood [4-6].  In this essay I contend that neuroangiogenesis (NAG) is also essential 
throughout adult life (albeit at a low level) for maintaining the microcirculation of the 
cerebral cortex and elsewhere in the brain and that it declines with aging, leading to a 
reduced cerebral capillary density (CCD) in the elderly – a condition fully reported and 
reviewed below.  This may account for the memory loss and vascular cognitive impairment 
(VCI) observed in many older persons and for the common form of Alzheimer’s disease (AD).  
VCI includes mild to severe cognitive decline, while the extreme state is called vascular 
dementia (VaD) [6]. 
This essay is outlined in some detail to enable thereader to find and focus on those 
areas of specific interest.  It begins with a section covering background information on 
cerebral capillaries and angiogenesis.  The following three sections summarize reports on 
CCD and NAG during the three stages of life (postnatal, maturity, senescence).  Data in each 
are presented first from human subjects and then from experimental animals.  Next are 
cited studies on CCD and NAG in Alzheimer’s disease and other senile dementias.  The 
hypothesis proposed here is then discussed along with related or rival ones.  The final 
sections concern seven potential routes for administering angiogenic factors to the brain 
and the cautions to be observed when considering such treatment.      
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2.  Background:  CCD & NAG 
 Studies on cerebral microvascularity preceded by half a century the discovery of 
angiogenesis.  In the early 1920s, Edward Horne Craigie (1894-1989), a biologist at the 
University of Toronto, reported on capillary densityin various parts of rat brains by counting 
certain structural features of the capillaries in thinly cut slices (mostly 2-6 µm thick), where 
only segments of vessels remain.  The most widely used parameter has been the sum of the 
lengths of fragments visible in a fixed area of each brain slice over a fixed number of slices, 
yielding an Lv in µ/mm3 [8-12].  To exclude arterioles, only vessel fragments with diameters 
generally smaller than 12µm were included in these measurements [13].  Other indices of 
capillary morphometry employed by different investigators have been the number of 
capillary sprouts, capillary volume of fragments per unit volume of brain tissue (Vv, per mm3), 
capillary surface area/area of brain slice (Sv, per mm2), or the sum of capillary diameters in a 
given area (D) [11,14]. 
 More recent studies on brain sections have employed automated optical scanning 
systems to measure florescence staining by various antibodies to capillary endothelial 
markers:  phosphatase, transferrin, laminin, CD105, CD31, etc. [15-18].  The endothelial cell 
content of mouse brain tissue homogenates have also been analyzed on SDS-Page gels by 
immunoblot staining of capillary endothelial markers [18,19]   
I.C. (Isaac Chesar) Michaelson (1903-1983), a British ophthalmologist, studied capillary 
growth in the developing retina of man and cats and in 1948 was the first to postulate the 
existence of a vasculogenic factor [20].  In 1971 Judah Folkman (1933-2008) at Harvard 
Medical School reported isolating such a factor from various tumors but not from non-
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malignant tissues.  He proposed that solid tumor growth depends “on the continuous build-
up of a new capillary network” by his tumor angiogenesis factor (TAF) [21].  Angiogenesis is 
also a physiological response in various non-tumor conditions – e.g., during embryonic and 
fetal development, the formation of ovarian follicles and transiently in the corpus luteum 
during ovulation and during the development of the placenta.  Neovascularization is a vital 
part of wound healing and fracture repair but ceases when the tissue is fully recovered.  In 
contrast, uncontrolled angiogenesis promotes progressive solid tumor growth, occurs also 
during chronic inflammation, and is associated with over 70 human disorders, which Folkman 
grouped together as “angiogenic diseases.”  Among them are diabetic retinopathy, 
rheumatoid arthritis, psoriasis, etc. [22, 23]. 
Folkman’s isolation of TAF (c. 10 kDa) in 1971 was followed by the discovery of other 
endothelial growth factors.  Those listed below have been found in the brain.  The first 
identified from non-tumor sources was the fibroblast growth factor (FGF, 18 kDa) [24].  The 
most thoroughly examined angiogenic agent has been vascular endothelial growth factor 
(VEGF, 46-48 kDa), which was originally called vascular permeability factor (VPF) [25, 26].  It 
exists in five isoforms with VEGF165 being “the most abundant in the human brain” [27].  
Other brain-localized factors include epidermal growth factor (EGF, 6 kDa), transforming 
growth factor-beta (TGF-β, 5.5 kDa), and platelet-derived growth factor B (PDGF-β, 46kDa) 
[28-31].  PDGF-β is secreted by brain endothelial cells; the cognate receptor, PDGF-R, is 
located on brain pericytes. 
Another family of angiogenic factors includes angiopoietins which, like the family of 
VEGFs, are endothelial cell-specific cytokines whose cognate receptors  are expressed only 
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on ECs [27, 32].  The various factors/cytokines associated with angiogenesis have been 
thoroughly reviewed [27, 29, 33]. 
 
3.  CCD and NAG during Postnatal Development 
 CCD.  The most rapid growth of the human brain occurs between ages 3-6 years in 
the frontal lobes and from 6-15 years in the temporo-parietal region [34].  Diemer compared 
the capillary density in the frontal cortex of newborn infants and adults and found the 
former to be 98.4 capillaries/mm2 and the latter to be 290 cap./mm2 [4].  Rats have been a 
more accessible model for exploring cerebral microcirculation postnatally [12, 14].  In 1925 E. 
H. Craigie pioneered such studies in male albino rats from their birth to 13 months of age 
(Day 364).  Shortly before being sacrificed, each was injected with carmin gelatin to fill the 
cerebral vascular bed.  Craigie examined the five laminae (Brodmann’s layers) in each of five 
cortical areas for the total length of capillary fragments in a unit volume of brain tissue (Lv in 
µ/mm3).  Vascularity in all areas rose rapidly up through days 10 to 21 but only slowly 
thereafter.   In three cortical regions (praecentralis, occipitalis, and parietalis) vascularity rose 
further to a maximum in 13-month old rats [8]. 
NAG during postnatal life. The following two reports ascribe control of early 
postnatal neovascularization in the brain to an angiogenic mitogen.  1) Breier et al. 
determined that vascular endothelial growth factor transcript levels (VEGF mRNA) in mice 
are “abundant in the ventricular neuroectoderm of embryonic and postnatal [6-day] brain 
when endothelial cells proliferate rapidly but [are] reduced in the adult when [as the authors 
state] endothelial cells proliferation has ceased” [5].  2) Ment et al. concluded that “VEGF 
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may mediate reactive angiogenesis in the developing brain” based on observing that 
newborn rats subjected to sublethal hypoxia exhibited a 28% increase in vascular density in 
cortical areas and a 2.4-fold increase in VEGF mRNA [35]. 
 
4.  CCD and NAG during Maturity (Adulthood) 
CCD.  After the brain’s full development, the functional status of the cerebral 
microcirculation depends on the maintenance and repair of capillary endothelial cells.  The 
turnover rates for these cells inhuman or animal brainshave not been reported, but such 
values for endothelial cells elsewhere in the body of various animals are available from 
studies which employed thymidine labeling of capillary endothelium and autoradiographs of 
tissue sections [36, 37].  For example, in 1967 Engerman and co-workers found that 0.01% of 
the capillary cells in the adult mouse retina were labeled after a single injection of tritiated 
thymidine and interpreted this as a turnover time of three or more years [38].  More 
recently, based on the “mean of 14 studies” by numerous investigators, Denekamp 
concluded that the “potential turnover time” of capillaries of “normal tissues” is 60 days 
(6x/yr) [39].    
Again, none of the above values are for human cerebral capillaries.  However, 
adopting Denekamp’s mean value of 6x/yr as a possible turnover number in the human brain 
and assuming an average life span of 60 years after puberty, I calculate that cells in the 
cerebral capillary bed undergo 360 turnovers during the average adult’s life.  On the other 
hand, if one adopts here Engerman’s 3-year estimate of capillary endothelial turnover, then 
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these cerebral capillaries would undergo replacement twenty times during an average adult 
lifetime.   
NAG during maturity.  Whatever the true value, the repair or replacement of the 
cerebral microcirculation throughout human adulthood must require the presence of 
endothelial growth factors in the brain and a persisting low level of angiogenesis.   But the 
data for this are sparse.  Two groups have used Northern blot analysis to measure transcript 
mRNA levels.  Maxwell et al. examined the brains of patients with astrocytomas.  In the 
adjacent normal brain tissue they found “a weak expression of TGF-αmRNA [transforming 
growth factor] and near background levels of EGF-R mRNAs [epidermal growth factor] [30].  
Breier et al. studied adult mouse brains and reported that VEGF mRNA levels in the choroid 
plexus “appeared slightly reduced” compared with that in 6-day old post-natal brains [5].  
Angiogenesis was inferred by Black et al. in studies measuring the capillary density in 
the visual cortex in rats of various ages raised for 50 days under two different conditions – 
either paired together in a standard cage containing only bedding (= control group) or 
housed with 4-5 other rats in a complex/enriched environment containing toys, changed and 
rearranged daily (= enriched group).  Brain sections from the visual cortex (area 17) of both 
hemisphere of all rats were examined for capillary diameter and spacing (reflective of 
newcapillaries and angiogenesis).  These values were higher in enriched groups of all ages 
than in similarly aged control rats.  The authors also concluded that “2-year-old enriched 
animals [“old” rats] exhibit an impaired response to complex experience, in comparison to 
younger… counterparts,” and that “angiogenesis, while it does occur, is substantially 
impaired in the middle-aged animals” [40]. 
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The idea of a sustaining level of angiogenesishas been considered by others.  In 
discussing angiogenesis inhibitors in human beings, Carmeliet concluded that there are 
“threshold levels of VEGF for the survival and maintenance of quiescent vessels in healthy 
organs” [23].  Based on his studies in rats, Bär wrote that the maintenance of capillary 
plexusesor its repair “needs a continuous action of an angiogenetic stimulus” [41]. 
 
5.  CCD and NAG during Senescence (… in the absence of recognized dementia)  
 CCD.  The effect of aging on cerebral capillary density has yielded conflicting reports 
[42].  Riddle et al. published a summary which covered three decades of investigations (1971-
2001) concerning  such age-related changes and which listed14 reports of decreases (6 
human studies, 8 in rats) and seven with no decrease (3 human studies, 4 in rats) [43].  The 
following studies found decreased CCD in aged human subjects and rats.  
Impairment of cerebral capillaries in older persons was observed by Stewart and 
colleagues.  They obtained biopsy specimens from the neocortex and underlying white 
matter in patients ranging from 20 years to 80 years in age who underwent surgery for glial 
tumors or corticectomy for intractable epilepsy.  Tissue was removed from the frontal, 
parieto-occipital, or temporal lobes in areas “as distant as possible from tumor or 
epileptogenic focus.”  The wall thickness of capillaries from these areas was measured under 
electron microscopy at 12 equally spaced points around the entire perimeter [44].  Gray 
matter capillaries of the older subjects had 21% thinner walls than the younger ones (0.97µm 
vs.1.22 µm) and 28% thinner walls in their white matter (1.01 µmvs.1.40 µm) [44].  The authors 
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interpreted the age-related thinning as being caused by “a net loss of endothelial cells, with 
resultant elongation of the remaining cells” [44]. 
A deceased CCD was also observed by Abernethy et al. in the paraventricular nuclei of 
19 older human subjects, who ranged in age from 30 to 85 years and had no history of 
psychiatric treatment [15].  Somewhat related is an earlier study by Kuwabara and Cogan, 
who had noted a decline in the number of endothelial cells “in the capillaries of the 
peripheral retina in persons past middle life (50 years)” [45].  Studies comparing the brains 
of aged persons with those exhibiting senile dementia are presented in the next section.  
As previously mentioned, in the 1920s Craigie studied CCD in male albino rats from 
their birth to 13 months of age.  In three cortical regions vascularity rose further to a 
maximum in 13 month old rats, but in the two other regions (regioinsularis and temporalis) 
vascularity declined by that age [8].  In the region insularis it rose to a peak of 856µ at Month 
5 but fell to 638µ by Month 13.  And in regio temporalis a peak vascularity of 958µ was 
reached at Month 3 but fell to 855µ at Month 5 and was 850µ at Month 13 [8].  More 
recently, Buchweitz-Milton and Weiss recorded values for Lv (sum of capillary lengths in 
mm/mm3) in the cerebral cortex of “young” rats (8-10 months) as 830 and of senescent rats 
(28-33 months) as 577 [11].  
A decrease in “vascular elements” in the frontal and occipital neocortex of old rats 
was similarly observed by Klein and Michel, who measured various neocortical components 
(neurons, glial cells, vascular tissue) in young adult rats (6-8 months old) and aged ones (25-
27 months old) -- both of whom were challenged to master a complex maze.  Young adult 
rats succeeded after only 20 days.  Some old rats could do so and were termed “old maze-
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bright,” while others could not and was called “old maze-dull.”  Combined counts of 
neocortical vascular elements in the young adult group was 448, that for the old maze-
bright was 388 and for the old maze-dull was 314 [46]. 
NAG during senescence.  While angiogenic growth factors have been identified in 
adult/maturehuman brains (see above), no data are available on levels in neurologically 
healthy aged persons.  In a report cited earlier on capillaries in the visual cortex of rats 
housed under different environmental conditions (standard vs. enriched), Black et al. 
concluded that there is “a failure of angiogenesis in old rats” [40].  The following report by 
de la Torre contains observations which I have interpreted to indicate that angiogenesis 
wanes with age in rats.  In experimental support of his vascular hypothesis of human 
dementia (to be discussed later), he developed two rat models of chronic brain 
hypoperfusion.  These involved occluding for set periods both common carotid arteries (2-
VO) or both carotids plus the left subclavian artery [= left vertebral a.] (3-VO) [47].  Neither 2-
VO nor 3-VO elicited any sensory-motor deficits in the rats but did produce visuospatial 
memory impairment (VMI), as measured by the Morris water maze test.  Three different age 
groups of rats were studied with the following results.    
Young rats subject to 3-VO for 9 weeks recovered from VMI.   Middle age rats could 
survive 3-VO just beyond 8 weeks but did not recover following 3-VO for 9 weeks and 
developed degeneration of the CA1 hippocampal sector and eventually atrophic necrosis of 
parietal and temporal cortex.  Old rats (19-22 months) recovered following 2-VO for 1-2 
weeks but could not survive 3-VO much beyond 8 weeks.  These findings could be explained 
if angiogenesis in these rats declines with age.  By this interpretation the above middle aged 
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and older rats lacked the level of angiogenesis which young rats possessed and thus could 
not survive the more prolonged (9 weeks) or more severe (3-VO) hypoperfusion which the 
younger ones did.   
Until recently, the idea of a waning level of angiongenesis in aging human brains has 
received little detailed attention.  But in 1992 Ferrara et al. had noted that VEGF mRNA is 
expressed in rat brains and suggested that the “presence of the growth factor may be 
required to maintain the differentiated state of those vessels, which otherwise might 
undergo involution” [48].  His conjecture made two decades ago raises the question of 
cerebral capillary density and neuroangiogenesis in patients with various senile dementias.   
 
6.  CCD and NAG in Senile Dementias – mainly AD 
CCD.  Bell and Ball measured microvascular densities of capillaries and arterioles in 
the hippocampus of 3 groups:  normal young persons (mean age of 38 years), normal old  
(74 yrs.), and Alzheimer patients (78 yrs.) and recorded the overall mean values as 129, 108 
and 107 mm/mm3, respectively [49].  Fischer et al. examined four areas in normal vs. AD 
brains and found average vascular density indices (rounded off) as follows:  basal forebrain: 
87 vs. 43, hippocampus: 82 vs. 50, pre-frontal: 95 vs. 75, and motor/sensory: 94 vs. 83 [50].  
And finally, Buée et al. reported the “percentage of the ratio capillary surface area/cortical 
… field area” for three groups – young controls: 26.32%, elderly controls: 18.95%, and AD 
patients: 16.50% [51].  This subject has been extensively reviewed elsewhere [52, 53]. 
Many studies measuring capillary densities in AD brain have also described’’ physical 
abnormalities in the capillaries [50, 51, 54].  I have encountered no reports stating that such 
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abnormalities may precede a decline in capillary density, but this seems a plausible sequence 
in the progression of AD.  Ravens summarized the histological findings of vascular changes 
in the human senile brain beginning withthe study by Sir John Batty Tuke (1835-1913) in 1873 
and continuing to 1976 with the several papers by Fang and colleagues [55].  In 1992 Kalaria 
and Kroon described capillaries in Alzheimer’s disease as exhibiting “looping, kinking, and 
extensive tortuosity” [56].  In 1995 Kalaria and Hedera reported that over 90% of AD brains 
exhibit microvascular aberrations in neocortical tissue sections stained with antibodies to 
endothelial cell markers and basement membrane.  The abnormalities included “capillaries 
with collapsed or degenerated endothelium” [57].  Grammas et al. contend that 
“perturbations of the brain microvascular endothelium” may cause release of neurotoxic 
proteins in Alzheimer’s disease [58]. 
NAG in AD.  Below are five reports on the presence of endothelial growth factors or 
their mRNAs in Alzheimer patients.  Several papers suggest that the factors’ presence here 
represents an ineffective response.  1) In 1998 Kalaria et al. examined the brains of 12 AD 
subjects and found prominent VEGF reactivity in 40% of the cells resembling astrocytes.  The 
authors reasoned that this increased VEGF reactivity, which was “often localized around 
vessels,” might “compensate for insufficient vascularity and reduced cerebral perfusion in 
AD” [5].  
2) In 2004 Yang et al. reported that “VEGF is co-localized with Aβ plaques in the brains  
of patients with AD … most likely results in deficiency of available VEGF … [and] may 
contribute to neurodegeneration and vascular dysfunction in the progression of AD” [60].  
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3) In genome-wide expression profile studies, Pogue and Lukiw found in AD brains 
that the majority of specific mRNAs were down-regulated but that nine genes in a family 
having the potential to promote angiogenesis were up-regulated, with VEGF being the least 
elevated.  The authors concluded that any advance in angiogenic signaling may be the result 
of dysfunctional cerebral vasculature and may be “both a consequence and a contributing 
factor to etiopathology” of AD [61].     
4) Growth factors other than VEGF have been studied in demented and aged human 
brains.  Increased levels of basic fibroblast growth factor were found in association with the 
neuritic plaques and neurofibrillary tangles in AD brains.  The sequestered bFGF may 
represent a decreased “bioavailability to surrounding cells” [62]. 
5) Similar studies by Styren et al. showed increased levels of epidermal growth factor 
receptor on brain vascular endothelial cells of aged and demented persons (many with AD) 
as compared with neurologically normal subjects.  EGFR was interpreted here as a 
“proliferative signal” elicited by prior damage to the CNS or brain vasculature [63].   
However, in a different neurological disease Lambrechts et al. reported that VEGF 
plasma levels are 50% lower in persons with spontaneous amyotrophic lateral sclerosis 
(ALS).  They found that the intraperitoneal treatment of an ALS mouse model with VEGF 
“could prevent motorneuron death in ischemic conditions” [64].   
 
7.  Two Rival Ideas about the Etiopathology of AD:  Aβ vs. vascular 
  The presence of amyloid plaques and neurofibrillary tangles in the brain led Hardy & 
Higgins in 1992 to propose the amyloid cascade theory of Alzheimer’s disease [65].  Two 
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troubling reservations about this theory are that 1) “some humans without symptoms of AD 
have many cortical Aβ deposits” and 2) “the number of amyloid deposits in the brain does 
not correlate well with the degree of cognitive impairment” experienced by patients [66].  
However, in the face of theseobservations and as late as 2002, Hardy and Selkoe wrote that 
“an alternative hypothesis explaining the cause and early pathogenesis of AD that has as 
much experimental support as the Aβ hypothesis has not emerged” [66]. 
 Meanwhile, during the past two decades the pathogenesis of AD has been 
aggressively pursued along many new avenues of research.  Grammas noted that “the 
clinical entity AD has, by definition, been categorized as a ‘non-vascular’ dementia.”  This 
designation explains in part why “the role of neuro-vascular interactions in the evolution of 
neuronal injury in AD brain [had been] underappreciated” for so long [67]. 
The cerebral microcirculation attracted the attention of many students of AD, 
notably Jack C. de la Torre.  In 1993 he and Mussivand had reported on the “extensive 
angioarchitectural distortions of cerebral capillaries in Alzheimer’s brains” and proposed 
that “during ageing, brain capillaries ... may undergo progressive degeneration caused by 
amyloid deposits ... or genetic predisposition” [68].  In 1994 de la Torre ascribed a lowered 
cerebral blood flow in AD brain to various conditions, including “twisted, looped, and 
kinked” capillaries [69].  Over the next decade he defined risk factors responsible for the 
vascular disorder in AD persons – e.g., atherosclerosis, carotid artery pathology, diabetes, 
etc. [47, 70].  In 2010 he distinguished between cerebral hypoperfusion (a slow pathologic 
process involving many months or years) and cerebral ischemia (a more rapid progress 
involving only hours or days) [71].  Causes of the latter might be carotid artery stenosis, 
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strokes, etc.  In support of his general vascular theory of AD he cited the related studies of 
ten different laboratory groups [71]. 
Many others have pursued this vascular thesis [51, 52, 56, 58, 72-77].  Notable among 
them was Zlokovic, who in 2005 advanced a “neurovascular hypothesis of AD,” which 
maintains that the synaptic and neuronal dysfunction seen in AD is due to aberrant 
angiogenesis, faulty clearance of Aβ across the BBB, and senescence of the cerebral vascular 
system [78]. 
 
8.  Other Etiological Considerations Concerning AD -- Genetic, etc.  
  According to Wu et al., the above changes in AD listed by Zlokovic may reflect the 
low expression of the homeobox gene MEOX2 (mesenchyme homeobox, also known as 
GAX, growth arrest-specific homeobox) [79].  Genome-wide association studies show that 
three genes account for 10% or so of cases termed the early onset, or familial form of the 
disease [80].  But late onset AD and other forms of senile dementias may involve still other 
genes.   
Transcriptional profiling of brain endothelial cells from the frontal cortex of AD 
patients revealed that MEOX2 is one of 34 genes (out of 12,600 genes examined by Wu et 
al.) significantly altered compared with control age-matched autopsy samples [79].   MEOX2 
is a regulator of vascular differentiation, while the other 33 genes, which are variously up- or 
down-regulated in AD, encode transcriptional factors controlling diverse cellular events (cell 
differentiation, metabolism, apoptosis, etc.).   Wu reported that in AD cortical tissue the 
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capillary tubes were 65% fewer and the total capillary length was only 60% of controls.   
Deletion of Meox2 in mice resulted in reductions in brain capillary density.   
  Wu et al. transduced cultures of human brain endothelial cells with an adenovirus 
containing an oligonucleotide construct for Meox2 gene and found that the cells expressed 
“40% the level of GAX homeoprotein, formed 60% fewer capillary tubes, and had 
substantially lower survival rates after VEGF stimulation compared to controls” [79].  The 
authors suggested that in AD the low expression of MEOX2 activates a proapoptotic 
pathway, but the story is complicated by the presence of both apoptotic antagonists and 
apoptotic accelerators [80, 81].   
Genetics represents only one of the many promising avenues for basic research on 
AD.  Other aspects of the brain’s microvascular system are the associated non-neuronal cells 
– i.e., mural cells (smooth muscle cells & pericytes ensheathing the ECs) and adjacent glial 
cells (astrocytes, microglia, & oligodendrocytes).  Some of them are sources or targets of 
the various endothelial growth factors.  All are subjects of intense research [83, 84].  For 
example, Winkler et al. summarized the many reports about pericyte deficiency leading to 
BBB breakdown and brain hypoperfusion [85].  But the above topics and many others 
(hypoxia-inducible factors, BBB, Notch signaling pathways, Il-1β and other immunological 
factors influencing inflammation, etc.) are not discussed further here in order not to stray 
from this essay’s main theme -- CCD and NAG.  
 
9.  An Alternate Focus for AD & Senile Dementias:  Neuroangiogenesis 
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The hypothesis offered at the beginning of this essay proposes that during the life 
time of people, rats, mice, etc. the endothelial cells of cerebral capillaries, like most others 
cells in the body, deteriorate requiring repair by angiogenic factors.  As noted before, in the 
early 1990s Ferrara had speculated that the presence of VEGF in the adult kidney or brain 
“may be required in order to maintain the differentiated state of those vessels, which 
otherwise might undergo involution” [26]  The same idea was later expressed in a paper on 
retinopathy of prematurity by Alon, who wrote that “VEGF may act as a vascular survival 
factor” [86]. 
More precisely, I propose that after postnatal development, various growth factors 
(FGF, VEGF, EGF, TGF-α, angiopoietins, and maybe others yet to be identified) persist 
throughout adult life in the brain at low but progressively waning levels.  Some of these 
factors help maintain cerebral capillaries then and perhaps even generate additional ones, as 
in the primary motor cortex of heavily engaged concert pianists.  Following the general 
pattern of many hormones, such factors/cytokines in the brain commonly decline (I 
contend) during senescence, leading to a waning CCD which in time may account for a 
reduced cognition in aged persons and the emergence of AD.  
The hypothesis does not exclude a role for amyloid plaques and neurofibrillary 
tangles contributing to capillary disturbance and neuronal loss.  Indeed, Paris et al. found 
that Aβ inhibited capillary formation in three in vitro systems: 1) human brain endothelial 
cells (HBEC) plated on Matrigel, 2) CAM assay, and 3) bFGF-induced blood vessel formation 
in the corneal micropocket [87].  Also intra-tumor injection of Aβ inhibited vascularization of 
several different human tumor xenografts in nude mice [87].  
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10.  Challenges to the NAG Hypothesis of AD 
Two papers represent challenges to the NAG hypothesis, for one concludes that 
neuroangiogenesis is increased in AD and the other contendsthat treatment of AD should 
involve suppression of neuroangiogenesis.  
Paper #1.  Biron et al. noted that the well-recognized increased permeability of the 
BBB in AD has usually been blamed on cerebral hypoxia and neuroinflammation, but the 
authors suggested that instead the leakage may be due to neoanagiogenesis and 
hypervascularization induced by amyloidogenesis [18].  This conjecture was based on their 
human and mouse studies in which various markers of microvascular density (MVD) and 
tight junctions (TJ) were targeted/labelled with primary antibodies, which were then 
revealed by secondary antibody staining and measured by confocal microscopy [17].  For 
example, MVD “was defined as a ratio of the TFA (total fluorescence area in µm2 in 
hotspots) to total area of an imaged field and was used as a surrogate measure of 
angiogenesis” [18].  Some of the results of this very detailed paper are abstracted below. 
Biron et al. assessed microvessel density in human brains with AD and those with no 
disease (ND) using sections stained with a primary antibody to laminin.  This marker for 
basement membrane was used here as a measure of MVD [88].  In AD brains compared with 
ND brains, the MVD appeared 69% higher in the cerebral cortex sections and 60% higher in 
the hippocampal sections – reflecting, according to these investigators, hypervascularity in 
the former.  (I derived the above percentages from data given in the text.)  These findings 
contrast with the reduced CD in AD brains reported in most previous studies and may reflect 
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different assays employed – i.e., confocal fluoroscopy used here  versus the more tedious 
visual counting of capillary segments in brain sections, as described earlier in this essay. 
Biron et al. also used transgenic AD model mice (TgAPPsw line 2576), which 
overexpress the human amyloid precursor protein.  He examined them for markers of 
vascular density (CD 105), apoptosis (caspase-3), and tight junctions (occludin, ZO-1).  
Compared with normal littermates, the brains of aged Tg 2576 mice showed an enhanced 
MVD.  From the data given in the text, I calculate an 80% increase in the neocortex and a 60% 
increase in the hippocampus.  There were “significant disrupted tight junctions” but no 
evidence of vascular apoptosis [18].  The authors inferred that the BBB leakage was due to 
the increased microvascularity/angiogenesis. 
The above findings of an increased MVD in the transgenic AD mice contrast with the 
decreased vascular densities in Tg2576 AD mice reported by Paris et al. [89].  Using an 
automated optical fractionator/scanner, they examined the cortical and hippocampal 
sections of 3-, 9-, & 17-month old TgAPPsw and control littermates after immunostaining 
with PECAM-1 (platelet endothelial cell adhesion molecule = CD31).  Compared with the 
controls, the TgAPPsw mice of all ages showed reductions in vascular density in both brain 
areas – 33% in the cortex and 32% in the hippocampus [my calculations derived from Fig. 4].  
These data led Paris et al. to suggest “that the overexpression of APPsw in the vasculature 
may oppose angiogenesis” and to conclude that Aβ peptides have “profound anti-
angiogenic effects in vitro and in vivo” [89].   
In discussing the above discrepancy, Biron et al. wrote that “PECAM [a.k.a., CD31] is 
not favoured as an angiogenic marker as compared to CD105,” since PECAM is present 
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elsewhere than on the panendothelium, such as stromal or inflammatory cells [18, 90].  But 
if CD31 is less specific/more widespread  than CD105, then the lowered CD reported by Paris 
et al. seems to me all the more impressive.  Finally, early students of CCD worried about 
tissue shrinkage producing erroneously high counts [49].  The same concern was recently 
raised in studies on microglial clusters in AD [88].  The discrepancy between these two 
reports remains unresolved. 
 In any case, I suggest that the BBB leakage noted in Biron’s study and similar ones 
may represent abnormal neoangiogenesis, reflecting an imbalance of vascular growth 
factors – e.g., perhaps a predominance of VEGF (a.k.a., VPF, vascular permeability factor) 
over angiopoietin.   
Paper #2.  Vagnucci and Li also linked Alzheimer’s disease with angiogenesis in a way 
quite different from that proposed in this essay.  They stated that “the brain endothelium 
secretes the precursor substrate for β-amyloid plaque and a neurotoxic peptide that 
selectively kills cortical neurons.”  Since long term use of various non-steroidal anti-
inflammatory drugs “seems to prevent Alzheimer’s disease,” they concluded that “this 
benefit is largely due to these drugs’ ability to inhibit angiogenesis.”  They suggested that 
“antiangiogenic drugs targeting the abnormal [sic] endothelial cell might be able to prevent 
and treat this disease” [91].  The authors used the phrase “abnormal endothelial cells” 
without explaining it further.  The 12 drugs listed in their Table 2 have effects other than anti-
angiogenesis which may be altering the clinical course of AD.  Any “abnormality” in this 
system may have been due to an imbalance of angiogenic growth factors elicited, as I 
postulated above. 
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11.  An Approach for Treating Cerebral Microvascular Hypoperfusion 
Folkman’s research on angiogenesis included efforts to develop anti-angiogenesis 
agents (e.g., Avastin, a monoclonal antibody) which investigators have used to suppress the 
vascularization of solid tumors and to treat various angiogenic diseases [27, 91].  The reverse 
side of the angiogenic coin concerns promoting capillary formation [92, 93].  Folkman 
wondered whether “purified angiogenesis factors [could] be administered in vivo, either 
locally or systemically, to accelerate the healing of wounds and fractures, or to increase 
neovascularization in the ischemic or infarcted heart” [22].  Others have pursued this idea in 
people, dogs, and rabbits [94-96].  In 1992 Wang examined cerebral blood vessel 
development in postnatal mice with videomicroscopy and was led to propose studies 
involving “localized application of angiogenic factors in the brain” [12].  The following seven 
reports (1-7) describe growth factors being administered directly into the brain of 
experimental animals.  Some of these authors had in mind using a similar approach in the 
future for treating people with ischemic brain conditions, such as strokes. An eighth report 
(8) concerns exogenous VEGF which “ameliorated the cognitive impairment” in transgenic 
AD mice.  
1.  In 1990 Puumala et al. infused a high dose of basic fibroblast growth factor (HBGF-
2, or heparin binding growth factor) into the left lateral ventricle of the brains of Wistar rats 
six times over 26 days.  Four days after the last infusion, the cerebral vessels of the 
experimental and control animals were injected with carbon black and their brains removed 
for sectioning.  Eight areas of each brain were examined.  Only the section taken from the 
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left perilateral ventricular cortex showed a significant increase in capillary count compared 
to the same section in the sham operated animal.  Here the capillary density in the 
parenchyma adjacent to the left lateral ventricle was 315/mm2 compared to 261/mm2 in the 
same area in the control animal [97].    
2.  Using VEGF, Rosenstein performed similar experiments on young adult Wistar rats 
whose brains were cannulated to a 3 mm depth at a site posterior to the coronal suture and 
lateral to the sagittal suture [98].  During 7 days an osmotic minipump delivered 0.05µg/ml 
recombinant VEGF at 1 µl/hr and in the process produced a cavity.  In other rats a comparable 
cavity was produced via a control infusion.  In the VEGF-treated rats the infusion site was 
filled with “remarkably vascular tissue” containing vessels which were “tortuous and dilated 
and lacked uniform spacing” [98]. 
3-5.  Recombinant VEGF165 was also used by three other laboratory groups in rats 
subjected experimentally to middle cerebral artery (MCA) occlusion for 90 minutes on Day 0.  
Hayashi employed a ligature occlusion technique (Day 0), applied Gelfoam impregnated with 
9 ng of VEGF165 to the surface of the cerebral cortex through a burr hole on Day 1, and 
sacrificed the animals 24 hrs later (Day 2) [99].  Zang applied a fibrin clot, injected rhVEGF165 
(1 mg/kg) intravenously via a pump 48 hours later (Day 3), and removed the brains on Day 9 
[100].  Sun occluded the MCA with a suture, administered VEGF165(10 µg/ml) via an osmotic 
minipump into the left lateral ventricle (at 1 µl/hr x 3 days), and sacrificed the animals at 
various times thereafter [101].  The infarct volume was measured in allbrain sectionsand 
found to begreatly reduced in the treated animals compared with control animals.  The 
results of these three occlusion studies are summarized below.  
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Hayashi reported that the mean infarct volume of the sham-treated rats was 33% of 
their ipsilateral hemisphere, while that of the six VEGF-treated rats was only 18%. The interval 
between treatment and sacrifice was too short for angiogenesis to occur in the penumbra of 
the cortex and suggests a protective action on the capillaries of the factor absorbed from 
the Gelfoam.  Zang’s 9-day interval would have allowed time for the formation newly grown 
vessels.  Sun concluded that VEGF reduced the infarct size in his rats and enhanced cerebral 
angiogenesis and neurogenesis [101].   
6.  Similar studies by Kanya and by Wang in mice involved MCA occlusion and 
treatment within transventricular doses of VEGF.  Both showed improved motor and 
memory functions compared with untreated mice [102, 103].   
7.  Thau-Zuckman et al. subjected mice to traumatic brain/closed head injury and then 
infused VEGF into the lateral ventricles.   In comparison with untreated mice, they found 
increased numbers of “proliferating cells in the subventricular zone and in the perilesion 
cortex,” indicating augmented angiogenesis at the site of injury and reduced lesion volumes 
there [104].  
8. Finally, Wang et al. used the transgenic AD mouse model designated PDGF-
hAPPV7171 (platelet-derived growth factor). These mice were given intraperitoneal injections 
of VEGF x3 days.  Based on Morris water maze testing, they exhibited improved learning and 
memory.  Hippocampal areas showed “new blood vessel formation” by the 7th and 14th days 
after treatment but fell to the control level by the 28th day [105].  
In summary, numerous investigators have shown in brain-injured animals that VEGF 
administered into the ventricle contiguous to the injury reduces the ensuing cerebral deficit 
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for a time.  VEGF injections in transgenic AD mice induced a transient angiogenesis and 
increased microvasculature.  In her 2011 review on AD, Grammas discussed many of the 
above reports and topics, speculated about an “unexplored connections between 
angiogenesis and AD,” and suggested that “new therapeutic approaches are desperately 
needed” [67].  And also in 2011 Carmeliet and Jain wrote, “The revascularization of ischaemic 
tissues would benefit millions, but therapeutic angiogenesis remains an unmet medical 
need” [33]. 
 
12.  Seven Potential Delivery Systems for Treating Senile Dementias 
 The experimental brain injuries employed in experiments described above (carotid 
artery occlusion and local brain trauma) were acute cerebral events and contrast with the 
slow development of senile dementias in people.  Nevertheless, these animal studies 
suggest that providing angiogenic factors chronically to the human brain might retard or 
ameliorate cerebral microvasculopathies associated with aging – i.e., VCI and AD.    
Recent investigators have cautioned against the use of a single endothelial growth 
factor in therapeutic efforts to correct various vasculopathies, such as strokes, etc.  As early 
as 2000 Yancopoulos et al. wrote that many members of the VEGF, angiopoietin, and ephrin 
families interact in a complementary and coordinated manner to form functional vessels 
without leaks, etc.  They noted that the random delivery of “a single growth factor to 
reconstitute a vascular bed is now viewed as “somewhat naive and even misguided” [106].  
In 2002 two papers reported on the synergism of VEGF and angiopoietin-1 (Ang1) in 
angiogenesis and warned that using VEGF alone risks the growth of leaky vessels [107, 108].  
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Manoonkitiwongsa et al. advised against “VEGF monotherapy” for treating stroke victims 
for fear of induced angiogenesis with BBB leakage [109].  And recently Thau-Zuchman 
emphasized that in treating traumatic brain injuries VEGF alone “could be a double edged 
sword” by increasing vascular permeability and exacerbating cerebral edema [104]. 
Seven potential modes of administering angiogenic factors to the brain are discussed 
below and involve broadly speaking the blood circulation, the CSF, the subarachnoid space, 
or the olfactory/trigeminal nerves.  An important corollary of the NAG hypothesis is that 
more than one factor may be involved in producing functional capillaries.  Thus in discussing 
the therapeutic approaches below, I will generally refer to “factor or factors,” factor/s, or 
VEGF et al. 
#1.  VEGF along with a complementary factor/s could be given intravenously over 
many months via a programmable minipump placed subcutaneously in the body [110-112].  
But such an IV treatment has the potential to stimulate angiogenesis throughout the body 
and not be limited to the brain, where it is sought.  The desired localization might be 
achieved by chemically linking the factor/factors to an antibody specific for some antigen on 
capillary endothelial cells.  There is a high concentration of transferrin receptors on the 
luminal surface of capillaries “throughout the entire cerebrovascular bed” [16].  A mouse 
monoclonal antibody (OX-26) is specific for these receptors in rats.   
The potential success of this approach using VEGF et al. coupled to OX-26 is 
suggested by the following two studies.  When methotrexate was conjugated to OX-26 and 
the complex was injected intravenously, the drug was released across the blood brain 
barrier into the rat brain parenchyma [113].  Similarly, when the complex of nerve growth 
26 
 
factor and OX-26 was injected IV, NGF was observed within the rat brain capillaries and brain 
parenchyma, while it was not found there when injected alone [114]. 
#2.  An alternative route via the cerebral spinal fluid has some precedent in studies on 
Parkinsonian patients in whom nerve growth factor (NGF) has been infused over a 12-month 
period into the lateral ventricle with the expectation that it would spread from the CSF into 
the adjacent nigrostriatal dopamine system [115].  Kordower stated that “NGF will diffuse 
readily from the ventricular space into brain parenchyma” of the basal forebrain [116].  In the 
case of VCI and AD patients, introducing VEGF et al. via a ventricle would allow the factor 
also to reach the surface of the cerebral cortex chronically, since the CSF circulates through 
the subarachnoid spaces over the pia mater covering the cerebral hemispheres.   
#3.  A more direct route would entail injecting the factor/s into the subarachnoid 
space over the cerebral hemispheres through catheters (1 mm outer diameters) containing 
multiple draining holes -- like those used in intraputamenal infusion studies [117]. 
#4.  Another focused approach might involve the angiogenic factor/s coupled to 
magnetic nanoparticles (MNP, 2-10 nm).  Here the complex/complexes introduced into the 
body via the blood or CSF would be directed to the cerebral capillaries or cerebral pia mater 
and held there by a magnetic field over the skullcap.  “A simple external magnetic field is all 
that is necessary to target a drug [coating a nanoparticle] to a specific site inside the body” 
[118].  Such particles can “be retained at the site by application of a magnetic field gradient” 
[119].  For example, a study on stent angioplasty employed an anti-restenotic agent 
(paclitaxel) loaded onto magnetic nanoparticles and subjected to a uniform induced 
magnetic field at the stent site.  The authors reported a 4- to 10-fold higher concentration 
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there of drug-loaded particles than of the agent injected alone [120].  Such a delivery system 
consists of three parts: a magnetic core (e.g., magnetite, Fe3O4), a surfacecoating (e.g., 
polyethylene glycol, etc.), and a functional outer coating (e.g., a drug or factor) [119].  
5.  A general approach for introducing an angiogenic factor or factors overlying the 
cerebral parenchyma is suggested by Folkman’s work with sustained-release polymers 
implanted in rabbit corneas and other sites.  In his studies, nanogram (10-9g.) quantities of 
tumor angiogenesis factor (TAF) were released and became therapeutically available over 
weeks to months [121, 122].  The therapeutic level of an angiogenic factor/s needed in the 
brain is a key concern.  Rosenstein reported that cultures of fetal, neonatal, and adult rat 
neocortical explants treated with human recombinant VEGF showed “a dose-dependent 
increase in the ratio of vascular area/total explants area” over the range of 1-25ng [98].  
Kurachi found that neovascularization on the chick chorioallantoic membrane occurs at 
femtomolar levels (10-15g.) of angiogenin [123].  Parenthetically, Murray et al. noted that 
incorporating albumen in the polymeric delivery system allowed release of picogram (10-12 g.) 
quantity/day of epidermal growth factor (EGF) [124].  
The use of sustained-released systems has been described in recent publications 
from the Department of Neurosurgery at Johns Hopkins University School of Medicine for 
the delivery of anticancer agents directly to sites of excised gliomas.  Here the drugs were 
incorporated in biodegradable polyanhydride wafers (Gliadel wafers) placed in the excised 
site [125, 126].  Various studies in rats have employed four different intracranial resorbable, 
slow sustained release systems -- surgical foam, a thermal gel depot, a microcapsule, or 
biodegradable polymer beads [126-130].  If such a slow release device containing an 
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angiogenic factor/s were placed on the pia mater covering the cerebral cortex of persons 
with incipient VCI or AD, the factor/s might be absorbed into the parenchyma and help 
maintain existing capillaries or stimulate local capillary production over the long term.  A 
locally applied device or system would prove more effective in the case of a factor having a 
short half life in the blood when administered systemically.     
In light of the brain-penetrating therapies being tested in Parkinson’s disease (e.g., 
intraventricular and intraputamenal infusions over many months), it is not implausible to 
consider two less invasive approaches for the chronic administration of an angiogenic 
growth factor merely to the brain surface – i.e., perfusion through multiple small holes in the 
skull or via trephination.  The former route might involve VEGF bound to biodegradable, 
slow-release polymer beads, which are introduced via multiple microholes through the 
skullcap into the subdural space over the cerebral cortex [130].  
 #6.  The latter route (trephination) might employ VEGF et al. in biodegradable 
polyanhydride wafers, which are distributed over the pia mater of the cerebral cortex 
through burr holes.  Trephining has been a simple, successful operation performed since the 
Neolithic Age in Europe.  Long before modern anesthesia and knowledge of asepsis, persons 
underwent trephination multiple times and recovered, as judged by the smooth, healed 
edges of the bony hole in their skulls.  One ancient Inca patient in Cuzco, Peru survived 
seven successive operations with seven healed burr holes in his skull [131].  Today the 
operation can be performed in an outpatient setting in 20 minutes or so and requires only a 
local anesthetic to deaden pain in the epicranium.  
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#7.  Another potential route involves the nasal cavity, where macromolecules may be 
absorbed across the olfactory membrane (olfactory receptor cells) and reach the brain 
parenchyma.  For example, when gelfoam was soaked in a wheat germ agglutinin-
horseradish peroxidase solution (WGA-HRP) and inserted into the nose of rats, neurons 
labeled with WGA-HRP were found “in the midbrain and pons and throughout the entire 
expanse of the olfactory cortex to the caudal pole of the cerebral hemisphere” [132].  Similar 
studies were reviewed by Illum [133].  
Recombinant human nerve growth factor (rh NGF, Mw 37 kDa) given by nose drops to 
anesthetized rats was measured in the brain by enzyme-linked immunosorbent assay and 
found to reach concentrations within an hour of 3400 pM in the olfactory bulb and 660-1300 
pM in four coronal sections of the cerebral hemisphere taken from anterior to posterior 
[134].  The authors of this 1989 paper suggested using this route for the long term treatment 
of Alzheimer’s disease with nerve growth factor (NGF) [134].  
Intranasal insulin is being tested in a 4-month long clinical trial in “adults with 
amnestic mild cognitive impairment or Alzheimer disease” [135].  Daily doses of an insulin 
aerosol are inhaled deeply via a drug delivery device.  A variation of this study could examine 
the effects of long term administration of angiogenic factors intranasally to persons with VCI 
and AD.   Agents encapsulated in cationic liposomes or onto nanoparticles and administered 
nasally show an increased absorption [136, 137].  
A small fraction of an agent administered nasally is absorbed by the ophthalmic 
branch of the trigeminal nerves and reaches the posterior part of the brain [138].  When 
insulin-like growth factor-1 was administered to rats intranasally, the factor appeared within 
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30 minutes in the rostal brain areas near the olfactory bulb and in “caudal areas near where 
the trigeminal nerve enters the brainstem” [139]. 
 
13.  Conclusion 
 The hypothesis advanced here attributes the vascular cognitive impairment (VCI) of 
old age and most cases of Alzheimer’s disease (AD) to a reduced cerebral capillary density 
(CCD) and an underlying declining (or aberrant) neuroangiogenesis (NAG).  Various 
mechanism not discussed in detail here determine the level of endogenous angiogenic 
factors in the brain throughout life.  I suggest that treatment with comparable exogenous 
factors may correct the deficiency or imbalance presumed to be responsible for VCI and AD.  
The NAG hypothesis, if valid, has practical implication for preventing or reducing the 
incidence of these conditions and possibly ameliorating the existing states.  Seven 
therapeutic approaches have been discussed for introducing angiogenic factors into the 
brain.  Effective treatment will likely involve a careful balance of several exogenous factors 
in order to preserve or revive a healthy cerebral microcirculation.  In future clinical studies on 
VCI and AD, investigators will be challenged to determine the most effective and safest 
combination of angiogenic factors. 
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